+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial



Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial



Annals of Internal Medicine 143(5): 317-326



Background: Patients with chronic obstructive pulmonary disease (COPD) frequently develop exacerbations, leading to major clinical and health resource use ramifications.Objective: To prospectively evaluate the effectiveness of a long-acting inhaled anticholinergic bronchodilator, tiotropium, in reducing COPD exacerbations and exacerbation-related health care utilization.Design: Randomized, double-blind study.Setting: 26 Veterans Affairs medical centers.Patients: 1829 patients with moderate to severe COPD (mean baseline FEV1, 36% predicted).Intervention: once-daily tiotropium (18 mu g) or placebo for 6 months. Patients otherwise received usual care, except for other anticholinergic bronchodilators.Measurements: The coprimary end points were the percentage of patients with a COPD exacerbation and the percentage of patients with a COPD-related hospitalization.Results: Tiotropium significantly reduced the percentage of patients experiencing 1 or more exacerbations compared with placebo (27.9% vs. 32.3%, respectively; difference, -5.7 percentage points (95% CI, -10.4 to -1.0 percentage points); P = 0.037). Fewer tiotropium patients were hospitalized because of COPD exacerbation (7.0% vs. 9.5%, respectively; difference, -3.0 percentage points (CI, -5.9 to -0.1 percentage points); P = 0.056), although this difference was of borderline statistical significance. Analysis of secondary outcomes indicates that tiotropium may lengthen the time to first COPD exacerbation (P = 0.028) and reduce health care utilization for exacerbations, including the frequency of hospitalizations (P = 0.047), unscheduled clinic visits (P = 0.019), and days of antibiotic treatment (P = 0.015). Tiotropium did not statistically significantly reduce all-cause hospitalization rates.Limitations: Trial participants were enrolled from 1 health care system, and 99% were men. The follow-up period extended for only 6 months.Conclusions: Tiotropium reduces COPD exacerbations and may reduce related health care utilization in patients with moderate to severe COPD.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012448308

Download citation: RISBibTeXText

PMID: 16144890

DOI: 10.1016/s0084-3873(08)70166-4


Related references

Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator: A Randomized Trial. Yearbook of Pulmonary Disease 2007: 92-93, 2007

Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease. Expert Opinion on PharmacoTherapy 5(8): 1827-1835, 2004

Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease. Proceedings 17(3): 366-373, 2004

Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair ® versus HandiHaler ® in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial. International Journal of Chronic Obstructive Pulmonary Disease 11: 2859-2867, 2016

UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Evaluation of: Tashkin DP, Celli B, Senn S et al.: a 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 359(15):1543-1554. Expert Opinion on PharmacoTherapy 10(4): 719-722, 2009

Tiotropium: an inhaled anticholinergic for chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy 62(12): 1263-1269, 2005

Tiotropium: An inhaled anticholinergic for chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy 62(12): 1263-1269, 2005

A randomized, double-blind, placebo-control study of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Zhonghua Jie he He Hu Xi Za Zhi 33(7): 519-523, 2010

Tiotropium bromide: a long-acting anticholinergic bronchodilator for the treatment of patients with chronic obstructive pulmonary disease. International Journal of Clinical Practice 57(10): 906-909, 2003

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. Drugs in R&d 16(2): 217-227, 2016

Tiotropium: An inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 23(2): 183-189, 2003

Tiotropium (Spiriva) - a long-acting inhaled anticholinergic for the treatment of chronic obstructive pulmonary disease (COPD). Pneumologie 57(9): 519-525, 2003

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet. Respiratory Medicine 6(5): 337-344, 2018

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium. Annals of Internal Medicine 144(2): 147; Author Reply 148-9, 2006

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. European Respiratory Journal 19(2): 217-224, 2002